- SK pharmteco completed an FDA inspection of its La Porte, Texas facility with no Form 483 issued, achieving “No Action Indicated” (NAI) status.
- The inspection reviewed quality systems, manufacturing operations, and compliance processes, confirming adherence to regulatory standards.
SK pharmteco has completed a U.S. Food and Drug Administration (FDA) inspection of its small molecule manufacturing facility in La Porte, Texas, with no Form 483 observations issued. The inspection, conducted from 9 to 12 February 2026, concluded with a “No Action Indicated” (NAI) classification, indicating compliance with regulatory requirements.
The FDA’s general inspection covered the site’s quality systems and contract manufacturing operations. Inspectors reviewed warehouse activities, manufacturing processes, and analytical laboratories. The assessment included batch records, corrective and preventive actions (CAPAs), deviation and out-of-specification investigations, and change control procedures. The agency also evaluated equipment qualification, water systems, and validation processes.
“The successful completion of this FDA inspection directly reflects the commitment to excellence and strong quality culture of our La Porte team. Maintaining an NAI status is a significant achievement that continues to highlight the strength of our systems and disciplined approach to building quality into every step of the process. It ensures our customers can continue to rely on SK pharmteco for secure, compliant, and uninterrupted manufacturing of life-enhancing medicines.”
Kalen Minvielle, Head of Small Molecule, North America
The company stated that it works with the FDA on continuous improvement initiatives, including participation in the Quality Management Maturity (QMM) programme. This initiative recognises manufacturers that demonstrate progress beyond baseline compliance in quality and reliability.
The outcome of the inspection supports SK pharmteco’s operations across small molecule manufacturing and its broader CDMO activities, as the company continues to meet regulatory expectations across its global network.
